Loading
No insider purchase over the last 90 days. The latest, by Anfima NV, was filed 08 Apr 2024.
Insider Decl.
35
Thresholds
n/a
Buy Volume
€2M
1 ops. · all time
Sell Volume
€6M
12 ops. · all time
Who traded when
BuySaleCyrille Damany1 sale
Gautam Satpute1 sale
Irshad J. Khan1 sale
Neeti Chavan1 sale
Neeti Santosh Chavan1 sale
Rajesh Aher1 sale
+1 other insider
Since the insiders bought
- +29.5%Entry ₹103.00 · Close at T+365 ₹133.43
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Camlin Fine Sciences Limited Buy (bullish), based on 2 analysts. Average price target: ₹152.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,590 of 26,280 companies
34.7
score / 100
Value37
Quality32
FCF yld1.6%
Earn yld1.8%
EV/EBITDA21.1x
ROE-3.4%
Gross mgn39%
Net mgn1.6%
Debt/EBITDA6.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹89.34
Analyst consensus
2 analystsBuy
₹140.00Target ₹152.50(+71%)₹165.00
Income statement
Revenue₹17.1B
Gross profit₹6.7B39% margin
EBITDA₹1.1B6% margin
Net income₹276.3M0.3% margin
Valuation
PER (forward)11.0x
P/Book1.6x
Beta0.68
Balance sheet & cash
Market cap₹17.2B
Total debt₹7.2B
Free Cash Flow₹245M
Debt / Equity72%
Profitability & ownership
ROE-3.4%
ROA1.1%
% insiders44.2%
% institutions14.0%
Last declaration on 28 September 2026
Declarations35 total
1,000,000 shares@ ₹97.500.52% mcap100.0% of flowEquityMarket SaleSEBI:4c60f8eace4c6a38499e7bfa175412117a06ed4e
4,000 shares-ReleaseSEBI:85511cc8e179e0e84ca5e1945ee0371148f1793a
8,000 shares@ ₹137.000.0059% mcap100.0% of flowEquityMarket SaleSEBI:05f9672f626a4c970c24a7e7e21186f37802c36b
3,296,000 shares@ ₹106.401.63% mcap14.3% of flowEquity SharesSEBI:98c0274d86d4b521aebb6bc511a452f1fdf9d314
800,000 shares@ ₹104.670.40% mcap3.5% of flowEquity SharesSEBI:682909e95c9b6c01cea9cc7fb51b0d5c75c56042
2,500,000 shares@ ₹109.391.30% mcap11.4% of flowEquity SharesSEBI:82cc05c2de4b973505d2126bd943d3720be30390
1,250,000 shares@ ₹103.860.61% mcap5.4% of flowEquity SharesSEBI:4d0a11fb364da683effe84837869ecbdcfb503f6
650,000 shares@ ₹96.930.30% mcap2.6% of flowEquity SharesSEBI:fa46604ac29cc700c17437007b16151b4aa86ad6
700,000 shares@ ₹112.510.37% mcap3.2% of flowEquity SharesSEBI:e84963bf26149c81b2f5105ccc2a8e7f0cfe552d
625,000 shares@ ₹118.710.35% mcap3.1% of flowEquity SharesSEBI:14ef27c4d36edcb579cff7acd7dfac68d1e2d1f4
100,000 shares@ ₹144.930.6% of flowEquity SharesSEBI:f8b7e747ea4856a98ab5757e689100d75dfa3878
3,475,000 shares@ ₹142.6320.8% of flowEquity SharesSEBI:1957018746da050316ff64791e77aa4e6e7f4691
950,000 shares@ ₹144.935.8% of flowEquity SharesSEBI:7331760409d0a795b5d420cd4501d452134c178e
1,800,000 shares@ ₹142.2810.7% of flowEquity SharesSEBI:e0ec63709335b04aead16e283a0ebd9f7c10f63a
3,000,000 shares@ ₹148.2418.6% of flowEquity SharesSEBI:3055dd0c45a92fe177cbce2b59adcc4ea8432d1e
10,000 shares@ ₹85.00100.0% of flowEquity SharesSEBI:9cce1c8b789beafc4e5fbe33d42162dbe3b89987
24,420 shares@ ₹63.59100.0% of flowEquity SharesSEBI:4951fa0676e91f19dd431c99026728a4cf1c253c
4,750 shares@ ₹222.4878100.0% of flowEquity SharesSEBI:36d83df117869edc3f9f10baa210306eee1f9bcb
4,600 shares@ ₹245.5761100.0% of flowEquity SharesSEBI:810e9eec67d3b30dda73dc77bedf089e46192c00
3,592 shares@ ₹313.9154100.0% of flowEquity SharesSEBI:01a4840ec8f68b477af4a2870557bca045049c16
3,500 shares@ ₹323.5889100.0% of flowEquity SharesSEBI:90c67129da62eac5cf81e0ce4a740df5783b9dc9
7,300 shares@ ₹237.5047100.0% of flowEquity SharesSEBI:9dd5087f101f4f6f0beb860032e7ab1683846b89
508,000 sharesEquity SharesSEBI:3c73f7c33c82191f19700db0cf731fc412add1b3
508,000 sharesEquity SharesSEBI:1700886079559387485bc6e18aabeec01fce25fd
1,338,600 shares@ ₹102.731231.7% of flowEquity SharesSEBI:06890463027c5dd044b64758dfb19a12e04033c6
25 of 35 declarations
About Camlin Fine Sciences Limited
On April 5, 2024, a purchase and a sale of the same amount, EUR 2,490,641, are filed at Camlin Fine Sciences Limited: the purchase by Anfima NV, the sale by Ashish S Dandekar. It is the only purchase in the record of this Indian chemicals and materials company listed on the Bombay Stock Exchange, or 8% purchases among open-market trades, against 12 sales worth EUR 5,850,873 with a median of EUR 20,785.
The other large sales are those of Infinity Direct Holdings, EUR 1,476,509 on September 4, 2024, and of Cyrille Damany, EUR 892,391 on September 28, 2026. Ashish Subhash Dandekar, filed as a director, is the top filer with 12 filings, neither purchases nor sales, to which are added other entries under similar names: Ashish S Dandekar (4) and Ashish Subhash Dandekar as a promoter (1).
Read moreShow less
The record of 35 filings counts 20 filings of another kind and 2 grants. The year 2026 gathers 15, 2024 has 10. The last twelve months line up 15 filings, 2 of them sales. The 20 filers hold 44.2% of the capital, valued at INR 17.2 billion, and filings appear a median of 2 days after the trade.
